Highest-materiality recent filing
Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president
Andrew Miller, Ph.D., appointed to board effective May 27, 2026, filling vacancy after board size increased to seven.
Alto Neuroscience annual meeting: ESPP amendment approved, equity plan amendment fails
Stockholders approved amendment to 2024 ESPP to treat pre-funded warrants as shares for evergreen feature.
Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD
Net loss of $26.2M for Q1 2026 vs $15.2M in Q1 2025; R&D expenses rose to $20.3M.
Alto Neuroscience Phase 2 miss for ALTO-101; shifts focus to ALTO-207
ALTO-101 did not meet primary EEG or cognitive endpoints in Phase 2 CIAS study.
Alto Neuroscience raises $120M via PIPE to fund ALTO-207 Phase 3 in TRD
Gross proceeds ~$120M from sale of 2.9M shares at $20.00 and 3.1M pre-funded warrants at $19.9999.
Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026
Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.
Net loss $14.2M vs $16.8M in Q3 2024; R&D expense $10.5M, G&A $4.4M.
Alto Neuroscience raises $50M in PIPE; accelerates ALTO-207 in TRD after FDA meeting
Gross proceeds of ~$50M from PIPE led by Perceptive Advisors; priced at $5.914/share plus pre-funded warrants at $5.9139.
Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead
Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.
Alto Neuroscience reprices ~4.2M underwater options to $2.35 for employee retention
Total eligible options: 4,225,763 shares repriced to $2.35 from original range $2.44-$16.00 per share.
Alto Neuroscience identifies EEG biomarker and positive Phase 2 results for ALTO-203 in MDD
ALTO-203 showed pro-cognitive and wake-promoting effects; EEG theta/beta ratio confirmed as key biomarker (25µg: p<0.05).
Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's
Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).
Alto Neuroscience Q1 net loss $15.2M; cash $161.3M; key trial readouts on track
Net loss of $15.2M for Q1 2025 vs $13.4M in Q1 2024; R&D expense flat at $10.0M.
Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing
Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.
Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026
Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.
Alto Neuroscience enters $75M ATM equity offering; reports ~$168M cash as of Dec 31, 2024
Entered into sales agreement with Leerink Partners for at-the-market offering of up to $75M in common stock.
Alto Neuroscience expands credit facility to $75M, extends maturity to 2029
Maturity extended from Dec 2026 to Jan 2029; max facility raised from $35M to $75M.
Alto Neuroscience Q3 net loss $16.8M; ALTO-100 fails Phase 2b MDD primary endpoint
Net loss of $16.8M in Q3 2024 vs $9.1M a year ago; R&D expense $13.1M, G&A $5.8M.
Alto Neuroscience Phase 2b trial of ALTO-100 for MDD fails primary endpoint
ALTO-100 did not show statistically significant improvement on MADRS vs placebo in biomarker-defined MDD patients.
Alto Neuroscience Q2 2024 net loss $16.0M; cash $193.6M; Phase 2b MDD topline due Oct 2024
Cash, cash equivalents, and restricted cash of $193.6M as of June 30, 2024; expected to fund operations into 2027.
Alto Neuroscience secures up to $11.7M convertible loan from Wellcome for ALTO-100 Phase 2b trial
Up to $11.663M convertible loan from Wellcome Trust; $2M funded immediately, remainder upon milestones.
Alto Neuroscience appoints Michael Hanley as Chief Operating Officer effective May 20, 2024
Hanley receives $470,000 base salary, 40% annual performance bonus target, and option for 188,000 shares.
Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts
Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.
Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track
Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.
Alto Neuroscience appoints former Biogen CMO Maha Radhakrishnan to board
Dr. Radhakrishnan, age 54, appointed as Class I director effective March 8, 2024; term expires at 2025 Annual Meeting.
Alto Neuroscience files amended charter and bylaws effective upon IPO closing on Feb 6, 2024
Amended and restated certificate of incorporation filed with Delaware Secretary of State on Feb 6, 2024.
the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.
Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the "Board") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.
On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.
On May 21, 2024, Alto Neuroscience, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Michael Hanley as the Chief Operating Officer of the Company, effective as of May 20, 2024
On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC.
Max materiality 0.85 · Median 0.65 · Most common event earnings